海昇药业
(870656)
| 流通市值：4.66亿 | | | 总市值：18.64亿 |
| 流通股本：2500.01万 | | | 总股本：1.00亿 |
| 报告期 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 41,982,766.72 | 166,209,055.55 | 116,290,891.37 | 70,947,999.3 |
| 营业收入 | 41,982,766.72 | 166,209,055.55 | 116,290,891.37 | 70,947,999.3 |
| 二、营业总成本 | 28,758,458.48 | 117,608,153.68 | 79,543,652.56 | 45,293,703.41 |
| 营业成本 | 24,173,159.05 | 99,745,346.32 | 69,646,871.23 | 39,598,332.33 |
| 税金及附加 | 137,835.34 | 1,933,600.88 | 973,928.77 | 668,815.9 |
| 销售费用 | 350,806.23 | 2,174,544.68 | 1,715,601.14 | 1,016,730.54 |
| 管理费用 | 1,814,465.87 | 9,982,647.75 | 7,414,444.7 | 4,831,359.85 |
| 研发费用 | 2,693,987.3 | 9,577,097.56 | 6,151,349.94 | 4,047,841.27 |
| 财务费用 | -411,795.31 | -5,805,083.51 | -6,358,543.22 | -4,869,376.48 |
| 其中:利息收入 | 287,558.63 | 4,591,112.38 | 5,669,461 | 4,135,988.75 |
| 加:投资收益 | 1,573,001.46 | 4,877,691.2 | - | - |
| 资产减值损失(新) | 29,125.97 | -371,424.8 | - | - |
| 信用减值损失(新) | 65,850.11 | 712,447.27 | 620,585.27 | 832,209.91 |
| 其他收益 | 339,314.82 | 4,502,946.13 | 920,092.88 | 477,434.67 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | 15,231,600.6 | 58,322,561.67 | 38,287,916.96 | 26,963,940.47 |
| 加:营业外收入 | 4,000 | 71,639.83 | 4,605 | 4,605 |
| 减:营业外支出 | - | 40,300 | - | - |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 15,235,600.6 | 58,353,901.5 | 38,292,521.96 | 26,968,545.47 |
| 减:所得税费用 | 1,974,696.75 | 7,603,678.1 | 4,963,159.67 | 3,519,510.55 |
| 六、净利润 | 13,260,903.85 | 50,750,223.4 | 33,329,362.29 | 23,449,034.92 |
| 持续经营净利润 | 13,260,903.85 | 50,750,223.4 | 33,329,362.29 | 23,449,034.92 |
| 归属于母公司股东的净利润 | 13,260,903.85 | 50,750,223.4 | 33,329,362.29 | 23,449,034.92 |
| (一)基本每股收益 | 0.17 | 0.65 | 0.43 | 0.31 |
| (二)稀释每股收益 | 0.17 | 0.65 | 0.43 | 0.31 |
| 九、综合收益总额 | 13,260,903.85 | 50,750,223.4 | 33,329,362.29 | 23,449,034.92 |
| 归属于母公司股东的综合收益总额 | 13,260,903.85 | 50,750,223.4 | 33,329,362.29 | 23,449,034.92 |
| 公告日期 | 2025-04-25 | 2025-04-25 | 2024-10-29 | 2024-08-28 |
| 审计意见(境内) | | 标准无保留意见 | | |